Remove 2003 Remove Disease Remove Vaccine
article thumbnail

One coronavirus vaccine may protect against other coronaviruse

The Pharma Data

Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines that could prove useful in the face of future epidemics.

Vaccine 40
article thumbnail

Eclectic Genomics: Cat Flu, Dolphin Adaptation to Climate Change, Predicting Cancer, and Diagnosing Rare Disease

PLOS: DNA Science

That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. Seventeen of the entire group (10.7%) had “unanticipated monogenic disease risks (uMDRs).”

Disease 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Women in Stem with Andrea Pfeifer

Drug Target Review

From an early age, I’ve been passionate about finding cures for difficult-to-treat diseases. Then I was approached to co-found AC Immune in 2003. I accepted and I’ve been CEO ever since; our goal, from the beginning, was to pioneer new ways to diagnose, treat and prevent neurodegenerative diseases.

Disease 95
article thumbnail

Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.

The Pharma Data

NOTE: ADUHELM TM (aducanumab-avwa)injection 100 mg/mL solutionis indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Biogen Inc.

Disease 52
article thumbnail

Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial

The Pharma Data

Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. It is designed for use in a broad infant population, including all infants experiencing their first RSV season and infants with congenital heart disease or chronic lung disease entering their first and second RSV season.

Virus 40
article thumbnail

U.S. FDA ACCEPTS FOR PRIORITY REVIEW

The Pharma Data

FDA ACCEPTS FOR PRIORITY REVIEW PFIZER’S APPLICATION FOR TICOVAC (TICK-BORNE ENCEPHALITIS VACCINE). If approved, the vaccine may help reduce the risk of TBE for people traveling to endemic areas, potentially including military personnel serving in these locations. 1,2 If approved, TicoVac would be the first vaccine in the U.S.

FDA 52
article thumbnail

Defense-Forward Biosecurity

Codon

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. New Yorkers wait to receive a monkeypox vaccine.

DNA 81